Clinical trials: Irritable Bowel Syndrome Without Diarrhea

Irritable Bowel Syndrome Without Diarrhea

Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea

• Completed
• Age: 18 to 75 years
• Phase 2

The purpose of this study is to Evaluate the Optimal Dosage of Mosapride (Medirac) and Probitics in Irritable Bowel Syndrome Without Predominant Diarrhea.

Trial name

NCT01505777

Testing

Probiotics (Medirac)

Where

South Korea

Volunteers

280 people

Sponsor

Hanmi Pharmaceutical Company Limited